Verastem Inc
VSTM5.974USD
-0.106-1.74%
交易中 （美东）报价延迟15分钟
307.62M总市值
亏损市盈率 TTM
关于 Verastem Inc 公司
Verastem, Inc. 是一家后期开发生物制药公司。该公司的产品线专注于抑制癌症中促进癌细胞存活和肿瘤生长的关键信号通路的抗癌药物，特别是快速加速纤维肉瘤 (RAF)/丝裂原活化蛋白激酶 (MEK) 抑制和粘着斑激酶 (FAK) 抑制。该公司的先进产品候选药物 avutometinib 和 defactinib 正在进行临床前和临床研究，用于治疗各种实体肿瘤，包括低级别浆液性卵巢癌 (LGSOC)、非小细胞肺癌 (NSCLC)、胰腺癌、结直肠癌 (CRC) 和黑色素瘤。Avutometinib 是一种口服小分子 RAF/MEK 钳，可抑制 ras 肉瘤 (RAS)/RAF/MEK、ERK 丝裂原活化途径激酶 (MAPK) 通路。 Defactinib 是一种口服 FAK 和富含脯氨酸的酪氨酸激酶 (PYK2) 抑制剂。
公司简介
公司代码VSTM
公司名称Verastem Inc
上市日期Nov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
员工数量78
证券类型Ordinary Share
年结日Nov 08
公司地址117 Kendrick Street
城市NEEDHAM
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02494
电话17812924200
网址https://www.verastem.com/
公司代码VSTM
上市日期Nov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
178.97K
-9.20%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Ms. Michelle Robertson
Ms. Michelle Robertson
Independent Director
Independent Director
15.97K
+109.10%
Mr. Matthew E. (Matt) Ros
Mr. Matthew E. (Matt) Ros
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Julissa Viana
Ms. Julissa Viana
Investor Relations
Investor Relations
--
--
Dr. Paul Bunn, M.D.
Dr. Paul Bunn, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
178.97K
-9.20%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月30日 周三
更新时间: 7月30日 周三
持股股东
股东类型
持股股东
持股股东
占比
Balyasny Asset Management LP
8.71%
RTW Investments L.P.
7.73%
Logos Global Management LP
6.23%
The Vanguard Group, Inc.
6.23%
Point72 Asset Management, L.P.
6.08%
Other
65.02%
持股股东
持股股东
占比
Balyasny Asset Management LP
8.71%
RTW Investments L.P.
7.73%
Logos Global Management LP
6.23%
The Vanguard Group, Inc.
6.23%
Point72 Asset Management, L.P.
6.08%
Other
65.02%
股东类型
持股股东
占比
Hedge Fund
37.39%
Investment Advisor/Hedge Fund
19.69%
Investment Advisor
14.09%
Venture Capital
9.03%
Private Equity
7.93%
Research Firm
4.39%
Individual Investor
0.92%
Bank and Trust
0.09%
Insurance Company
0.03%
Other
6.43%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
221
44.66M
81.28%
-1.54M
2025Q1
244
43.61M
79.40%
-4.23M
2024Q4
235
34.35M
77.18%
-2.65M
2024Q3
242
27.08M
67.33%
+202.45K
2024Q2
244
15.08M
59.39%
-6.47M
2024Q1
256
17.10M
67.53%
-4.40M
2023Q4
273
17.07M
67.53%
-4.59M
2023Q3
291
17.14M
67.93%
-3.81M
2023Q2
301
16.47M
65.35%
+4.17M
2023Q1
312
8.40M
50.30%
-4.54M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Balyasny Asset Management LP
4.79M
8.71%
+842.05K
+21.34%
Mar 31, 2025
RTW Investments L.P.
4.25M
7.73%
+4.25M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.43M
4.42%
+118.60K
+5.13%
Mar 31, 2025
OrbiMed Advisors, LLC
2.86M
5.21%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
2.64M
4.81%
+1.74M
+193.84%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.33M
4.24%
+51.04K
+2.24%
Mar 31, 2025
Nantahala Capital Management, LLC
2.30M
4.18%
-1.45M
-38.75%
Mar 31, 2025
Marshall Wace LLP
2.23M
4.05%
+1.43M
+180.43%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
SPDR S&P Biotech ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
查看更多
SPDR S&P Biotech ETF
占比0.11%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.06%
iShares Micro-Cap ETF
占比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.03%
Fidelity Enhanced Small Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
公告日期
类型
比率
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
